Retinal Sensitivity in BRVO After Anti-VEGF Therapy

Fukushima Medical University50 enrolled

Overview

The efficacy of anti-vascular endothelial growth factor (VEGF) therapy for branch retinal vein occlusion (BRVO) is shown, but its effect on retinal sensitivity is not fully investigated. The purpose of this study is to compare the changes in retinal sensitivity after ranibizumab therapy or combination therapy of ranibizumab and laser photocoagulation in eyes with BRVO.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Branch Retinal Vein Occlusion

Interventions

RanibizumabDRUG

Ranibizumab and laserDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Treatment naive patients of branch retinal vein occlusion with visual acuity of less than 1.0 and macular edema of more than 250 micrometers in foveal thickness. Exclusion Criteria: * Patients with history of treatment for branch retinal vein occlusion, possibility of pregnancy, allergy for ranibizumab, intraocular infection, or severe inflammation will be excluded.

Locations (1)

Department of Ophthalmology, Fukushima Medical University

Fukushima, Fukushima, Japan

RECRUITING

Outcomes

Primary Outcomes

Retinal sensitivity measured by microperimetry (MP-3, NIDEK, Japan)

Time frame: At 12 months

Central Contacts

Akira Ojima, M.D., Ph.D

CONTACT

+81-24-548-2111 ao@fmu.ac.jp

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.